AstraZeneca PLC (AZN)
NYSE: AZN · Real-Time Price · USD
185.24
-0.09 (-0.05%)
May 29, 2026, 11:37 AM EDT - Market open
AstraZeneca Revenue
AstraZeneca had revenue of $15.29B in the quarter ending March 31, 2026, with 12.51% growth. This brings the company's revenue in the last twelve months to $60.44B, up 9.93% year-over-year. In the year 2025, AstraZeneca had annual revenue of $58.74B with 8.63% growth.
Revenue (ttm)
$60.44B
Revenue Growth
+9.93%
P/S Ratio
4.74
Revenue / Employee
$635,531
Employees
95,100
Market Cap
286.27B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 58.74B | 4.67B | 8.63% |
| Dec 31, 2024 | 54.07B | 8.26B | 18.03% |
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | 22.09B | -375.00M | -1.67% |
| Dec 31, 2017 | 22.47B | -537.00M | -2.33% |
| Dec 31, 2016 | 23.00B | -1.71B | -6.90% |
| Dec 31, 2015 | 24.71B | -1.84B | -6.93% |
| Dec 31, 2014 | 26.55B | 741.00M | 2.87% |
| Dec 31, 2013 | 25.81B | -2.17B | -7.75% |
| Dec 31, 2012 | 27.97B | -5.62B | -16.72% |
| Dec 31, 2011 | 33.59B | 322.00M | 0.97% |
| Dec 31, 2010 | 33.27B | 465.00M | 1.42% |
| Dec 31, 2009 | 32.80B | 1.20B | 3.81% |
| Dec 31, 2008 | 31.60B | 2.04B | 6.91% |
| Dec 31, 2007 | 29.56B | 3.08B | 11.65% |
| Dec 31, 2006 | 26.48B | 2.53B | 10.54% |
| Dec 31, 2005 | 23.95B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 96.36B |
| Merck & Co. | 65.77B |
| Pfizer | 63.32B |
| AbbVie | 62.82B |
| Novartis AG | 56.58B |
| Sanofi | 54.60B |
| Novo Nordisk | 50.57B |
| Bristol-Myers Squibb Company | 48.48B |
AZN News
- 2 hours ago - AstraZeneca says CARES Phase 3 clinical program did not meet primary endpoint - TheFly
- 6 hours ago - AstraZeneca Imfinzi combination approved in the U.S. - TheFly
- 9 hours ago - FDA Approves IMFINZI Combination With BCG For Non-muscle-invasive Bladder Cancer In Adults - Nasdaq
- 13 hours ago - AstraZeneca’s durvalumab approved in U.S. for NMIBC patients - TheFly
- 14 hours ago - IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer - Business Wire
- 15 hours ago - AstraZeneca (AZN) Receives FDA Approval for Imfinzi in Bladder Cancer Treatment - GuruFocus
- 20 hours ago - AstraZeneca (AZN) Gains FDA Approval for Imfinzi in Bladder Cancer Treatment - GuruFocus
- 20 hours ago - AstraZeneca (AZN) Secures U.S. Approval for Imfinzi Combination Therapy - GuruFocus